Rani Therapeutics Holdings, Inc. - Class A Common Stock (RANI)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Apr 3, 2026Investment Snapshot
- Piotroski F-Score 4/9 — moderate financial health
- ROE of 14.7% — below-average profitability
- Revenue growing at 59% annually
Rani Therapeutics Holdings, Inc. - Class A Common Stock (RANI) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $0 million . Key value metrics: Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Rani Therapeutics Holdings, Inc. - Class A Common Stock — Fundamental Analysis Summary
On financial health, RANI shows a moderate Piotroski F-Score of 4/9, and modest return on equity of 14.7% (sector average: -19.8%).
StockPik's composite Value Score for RANI is 58/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
RANI shows revenue growing at 59% year-over-year, with earnings growing at 1%.